title: The effect of inhibitors of platelet aggregation on the metabolism of platelet-activating factor (PAF) in washed rabbit platelets.
abstract: The rabbit platelet metabolizes platelet-activating factor (PAF) intracellularly. PAF is deacetylated to produce lysoPAF which, in turn, can be acylated to produce 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine (alkylacyl GPC). Some PAF receptor antagonists have been shown to inhibit this metabolic conversion. In the present study we examined whether the PAF receptor antagonists SRI 63-441 and WEB 2086 would inhibit the metabolism of PAF by intact rabbit platelets. In addition, we examined whether iloprost, a stable analogue of prostaglandin I2 (PGI2), and a potent inhibitor of platelet activation induced by a range of agonists, would also inhibit PAF metabolism. We found that SRI 63-441 and WEB 2086 caused an almost complete inhibition of the conversion of PAF to alkylacyl GPC. Iloprost caused up to a 50% inhibition of PAF metabolism compared to antagonist-free controls. Iloprost (and PGI2) is thought to inhibit platelet response by elevation of cAMP, while receptor antagonists act by blocking PAF binding to its receptor. Since iloprost caused partial inhibition of PAF metabolism, the results of this study suggest that inhibition of PAF metabolism does not occur solely due to competitive inhibition of PAF binding to its receptor.
authors.affiliation: Human Reproduction Unit, Royal North Shore Hospital of Sydney, St. Leonards, NSW, Australia.
authors.forename: C
authors.initials: C
authors.lastname: O'Neill
authors.forename: A J
authors.initials: AJ
authors.lastname: Ammit
authors.forename: R
authors.initials: R
authors.lastname: Korth
authors.forename: S
authors.initials: S
authors.lastname: Fleming
authors.forename: X
authors.initials: X
authors.lastname: Wells
mesh_terms: D000818:Animals; D001381:Azepines / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D016285:Iloprost / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D010972:Platelet Activating Factor / Q000031:analogs & derivatives / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011806:Quinolinium Compounds / Q000494:pharmacology; D011817:Rabbits; D014230:Triazoles / Q000494:pharmacology; D014316:Tritium
chemical_list: D001381:Azepines; C029271:O-deacetyl platelet activating factor; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D011806:Quinolinium Compounds; D014230:Triazoles; D014316:Tritium; C050531:SRI 63-441; C052518:WEB 2086; D016285:Iloprost